334 related articles for article (PubMed ID: 15789388)
1. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis.
Duong MH; MacKenzie TA; Malenka DJ
Catheter Cardiovasc Interv; 2005 Apr; 64(4):471-9. PubMed ID: 15789388
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
Zagler A; Azadpour M; Mercado C; Hennekens CH
Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis of contrast-induced nephropathy with N-acetylcysteine].
Gawenda M; Möller A; Wassmer G; Brunkwall J
Zentralbl Chir; 2007 Jun; 132(3):227-31. PubMed ID: 17610195
[TBL] [Abstract][Full Text] [Related]
6. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
Merkle M; Sauter M; Argirov M; Wörnle M
Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
[TBL] [Abstract][Full Text] [Related]
7. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
[TBL] [Abstract][Full Text] [Related]
9. Past and present attempts to prevent radiocontrast nephropathy.
Bailey SR
Rev Cardiovasc Med; 2001; 2 Suppl 1():S14-8. PubMed ID: 12439363
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine in cardiovascular-surgery-associated renal failure: a meta-analysis.
Nigwekar SU; Kandula P
Ann Thorac Surg; 2009 Jan; 87(1):139-47. PubMed ID: 19101287
[TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
12. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
[TBL] [Abstract][Full Text] [Related]
13. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points.
Hoffmann U; Banas B; Fischereder M; Krämer BK
Kidney Blood Press Res; 2004; 27(3):161-6. PubMed ID: 15256811
[TBL] [Abstract][Full Text] [Related]
15. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
[TBL] [Abstract][Full Text] [Related]
16. Effects of N-acetylcysteine on radiocontrast nephropathy in rats.
Yenicerioglu Y; Yilmaz O; Sarioglu S; Ormen M; Akan P; Celik A; Camsari T
Scand J Urol Nephrol; 2006; 40(1):63-9. PubMed ID: 16452059
[TBL] [Abstract][Full Text] [Related]
17. Significant statistical heterogeneity in a meta-analysis of the usefulness of acetylcysteine for prevention of contrast nephropathy.
Faddy SC
Am J Cardiol; 2004 Aug; 94(3):414. PubMed ID: 15276125
[No Abstract] [Full Text] [Related]
18. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
19. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
[TBL] [Abstract][Full Text] [Related]
20. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
